KR100847413B1 - 피리도인돌론 유도체 및 항암제 기재의 약제 조합물 - Google Patents

피리도인돌론 유도체 및 항암제 기재의 약제 조합물 Download PDF

Info

Publication number
KR100847413B1
KR100847413B1 KR1020037013925A KR20037013925A KR100847413B1 KR 100847413 B1 KR100847413 B1 KR 100847413B1 KR 1020037013925 A KR1020037013925 A KR 1020037013925A KR 20037013925 A KR20037013925 A KR 20037013925A KR 100847413 B1 KR100847413 B1 KR 100847413B1
Authority
KR
South Korea
Prior art keywords
formula
group
methyl group
cancer
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020037013925A
Other languages
English (en)
Korean (ko)
Other versions
KR20040015138A (ko
Inventor
베르나르 부리
피에르 카세야
장-마리 데로크
Original Assignee
사노피-아벤티스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피-아벤티스 filed Critical 사노피-아벤티스
Publication of KR20040015138A publication Critical patent/KR20040015138A/ko
Application granted granted Critical
Publication of KR100847413B1 publication Critical patent/KR100847413B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020037013925A 2001-04-27 2002-04-26 피리도인돌론 유도체 및 항암제 기재의 약제 조합물 Expired - Fee Related KR100847413B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR01/05843 2001-04-27
FR0105843A FR2823975B1 (fr) 2001-04-27 2001-04-27 Nouvelle utilisation de pyridoindolone
PCT/FR2002/001450 WO2002087575A1 (fr) 2001-04-27 2002-04-26 Associations pharmaceutiques a base de derives de pyridoindolone et d'agents anticancereux

Publications (2)

Publication Number Publication Date
KR20040015138A KR20040015138A (ko) 2004-02-18
KR100847413B1 true KR100847413B1 (ko) 2008-07-18

Family

ID=8862882

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037013925A Expired - Fee Related KR100847413B1 (ko) 2001-04-27 2002-04-26 피리도인돌론 유도체 및 항암제 기재의 약제 조합물

Country Status (33)

Country Link
US (3) US7524857B2 (enExample)
EP (2) EP1385513B1 (enExample)
JP (2) JP2004528343A (enExample)
KR (1) KR100847413B1 (enExample)
CN (2) CN1505511A (enExample)
AR (1) AR034313A1 (enExample)
AT (2) ATE314070T1 (enExample)
BG (2) BG108260A (enExample)
BR (1) BR0209138A (enExample)
CA (2) CA2443012C (enExample)
CY (1) CY1105813T1 (enExample)
CZ (2) CZ299465B6 (enExample)
DE (2) DE60208365T2 (enExample)
DK (2) DK1385512T3 (enExample)
EA (1) EA005930B1 (enExample)
EE (2) EE200300466A (enExample)
ES (2) ES2254683T3 (enExample)
FR (1) FR2823975B1 (enExample)
HU (2) HUP0400744A2 (enExample)
IL (4) IL158312A0 (enExample)
IS (1) IS2441B (enExample)
MX (1) MXPA03009639A (enExample)
NO (2) NO20034787L (enExample)
NZ (1) NZ528671A (enExample)
PL (2) PL366910A1 (enExample)
PT (2) PT1385513E (enExample)
RS (2) RS50790B (enExample)
RU (1) RU2292888C9 (enExample)
SK (2) SK13242003A3 (enExample)
TW (1) TWI252104B (enExample)
UA (1) UA74876C2 (enExample)
WO (2) WO2002087574A2 (enExample)
ZA (1) ZA200307785B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2823975B1 (fr) * 2001-04-27 2003-05-30 Sanofi Synthelabo Nouvelle utilisation de pyridoindolone
FR2846329B1 (fr) 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique
US7456193B2 (en) 2002-10-23 2008-11-25 Sanofi-Aventis Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics
FR2869316B1 (fr) * 2004-04-21 2006-06-02 Sanofi Synthelabo Derives de pyridoindolone substitues en -6, leur preparation et leur application en therapeutique.
FR2892416B1 (fr) * 2005-10-20 2008-06-27 Sanofi Aventis Sa Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880126A (en) * 1995-01-23 1999-03-09 Schering Aktiengesellschaft 9H-Pyridu ((3,4-b) indole derivatives

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1268772A (en) * 1968-03-15 1972-03-29 Glaxo Lab Ltd NOVEL alpha-CARBOLINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME
US4263304A (en) * 1978-06-05 1981-04-21 Sumitomo Chemical Company, Limited 7 H-indolo[2,3-c]isoquinolines
SU833971A1 (ru) * 1979-07-10 1981-05-30 Ленинградский Химико-Фармацевтическийинститут Способ получени 3-фенил-2-оксо- - КАРбОлиНОВ
SU833972A1 (ru) 1979-10-26 1981-05-30 Институт Физико-Органической Химиии Углехимии Ah Украинской Ccp Имидазо(4,5-с)пиридиний иодиды вКАчЕСТВЕ пРОМЕжуТОчНыХ пРОдуКТОВ дл СиНТЕзА фуНгицидОВ
FR2595701B1 (fr) * 1986-03-17 1988-07-01 Sanofi Sa Derives du pyrido-indole, leur application a titre de medicaments et les compositions les renfermant
US5035252A (en) * 1990-12-14 1991-07-30 Mondre Steven J Nicotine-containing dental floss
EP0581388A1 (en) * 1992-07-30 1994-02-02 Glaxo Group Limited Pyridoindolone Methansulphonate as 5HT and 5HT3 receptor antagonists
EP0755454B1 (en) * 1994-04-13 2008-02-13 The Rockefeller University Aav-mediated delivery of dna to cells of the nervous system
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
DE19624659A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
FR2765582B1 (fr) * 1997-07-03 1999-08-06 Synthelabo Derives de 3-alkyl-1,9-dihydro-2h-pyrido[2,3-b]indol-2-one leur preparation et leur application en therapeutique
FR2765581B1 (fr) * 1997-07-03 1999-08-06 Synthelabo Derives de 3-aryl-1,9-dihydro-2h-pyrido[2,3-b]indol-2-one, leur preparation et leur application en therapeutique
WO1999051597A1 (en) * 1998-04-02 1999-10-14 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-tetrahydro-9h pyrimidino[2,3-b]indole and 5,6,7,8-tetrahydro-9h-pyrimidino[4,5-b]indole derivatives: crf1 specific ligands
IT1313592B1 (it) 1999-08-03 2002-09-09 Novuspharma Spa Derivati di 1h-pirido 3,4-b indol-1-one.
US20020156016A1 (en) * 2001-03-30 2002-10-24 Gerald Minuk Control of cell growth by altering cell membrane potentials
FR2823975B1 (fr) * 2001-04-27 2003-05-30 Sanofi Synthelabo Nouvelle utilisation de pyridoindolone
FR2846329B1 (fr) 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique
FR2846330B1 (fr) 2002-10-23 2004-12-03 Sanofi Synthelabo Derives de pyridoindolone substitues en -3 par groupe heterocyclique, leur preparation et leur application en therapeutique
US6958347B2 (en) 2002-12-18 2005-10-25 Pfizer Inc. Aminophenanthridinone and aminophenanthridine as NPY-5 antagonists
FR2869316B1 (fr) 2004-04-21 2006-06-02 Sanofi Synthelabo Derives de pyridoindolone substitues en -6, leur preparation et leur application en therapeutique.
FR2892416B1 (fr) 2005-10-20 2008-06-27 Sanofi Aventis Sa Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880126A (en) * 1995-01-23 1999-03-09 Schering Aktiengesellschaft 9H-Pyridu ((3,4-b) indole derivatives

Also Published As

Publication number Publication date
CN1240382C (zh) 2006-02-08
DK1385513T3 (da) 2007-01-15
RU2003130376A (ru) 2005-04-10
CN1505511A (zh) 2004-06-16
CZ20032910A3 (en) 2004-07-14
US6967203B2 (en) 2005-11-22
CZ295224B6 (cs) 2005-06-15
CY1105813T1 (el) 2011-02-02
ZA200307785B (en) 2004-10-06
DE60208365D1 (de) 2006-02-02
US7160895B2 (en) 2007-01-09
EP1385513A1 (fr) 2004-02-04
EP1385512B1 (fr) 2005-12-28
ATE338548T1 (de) 2006-09-15
BG108261A (bg) 2004-12-30
CA2444334A1 (fr) 2002-11-07
JP2004528343A (ja) 2004-09-16
DK1385512T3 (da) 2006-05-22
PL366916A1 (en) 2005-02-07
FR2823975A1 (fr) 2002-10-31
US20040122027A1 (en) 2004-06-24
CN1505510A (zh) 2004-06-16
IL158312A0 (en) 2004-05-12
MXPA03009639A (es) 2004-06-30
NO20034785D0 (no) 2003-10-24
NO20034785L (no) 2003-12-23
RU2292888C9 (ru) 2007-06-20
PT1385512E (pt) 2006-05-31
AR034313A1 (es) 2004-02-18
NZ528671A (en) 2004-06-25
BG108260A (bg) 2004-12-30
ATE314070T1 (de) 2006-01-15
PT1385513E (pt) 2007-01-31
CA2443012A1 (en) 2002-11-07
UA74876C2 (en) 2006-02-15
YU83403A (sh) 2006-08-17
RS50790B (sr) 2010-08-31
TWI252104B (en) 2006-04-01
WO2002087574A2 (fr) 2002-11-07
KR20040015138A (ko) 2004-02-18
NO20034787L (no) 2003-12-23
EE200300465A (et) 2003-12-15
IL158266A0 (en) 2004-05-12
EP1385513B1 (fr) 2006-09-06
WO2002087575A1 (fr) 2002-11-07
US20050272760A1 (en) 2005-12-08
CA2443012C (fr) 2009-07-28
IS2441B (is) 2008-11-15
HK1060066A1 (en) 2004-07-30
SK13242003A3 (sk) 2004-03-02
HUP0400744A2 (hu) 2004-06-28
YU83903A (sh) 2006-08-17
RU2292888C2 (ru) 2007-02-10
US20040122036A1 (en) 2004-06-24
SK13252003A3 (sk) 2004-03-02
EP1385512A2 (fr) 2004-02-04
FR2823975B1 (fr) 2003-05-30
BR0209138A (pt) 2004-06-08
CZ20032909A3 (en) 2004-06-16
IS6984A (is) 2003-10-09
DE60214533T2 (de) 2007-06-21
WO2002087574A3 (fr) 2003-02-13
ES2271264T3 (es) 2007-04-16
HK1059895A1 (en) 2004-07-23
JP2004531538A (ja) 2004-10-14
DE60208365T2 (de) 2006-09-07
RS50791B (sr) 2010-08-31
HUP0400745A2 (hu) 2004-08-30
NO20034787D0 (no) 2003-10-24
US7524857B2 (en) 2009-04-28
ES2254683T3 (es) 2006-06-16
CZ299465B6 (cs) 2008-08-06
IL158312A (en) 2009-09-01
EE200300466A (et) 2003-12-15
PL366910A1 (en) 2005-02-07
DE60214533D1 (de) 2006-10-19
IL158266A (en) 2009-09-01
EA005930B1 (ru) 2005-08-25
EA200301062A1 (ru) 2004-04-29

Similar Documents

Publication Publication Date Title
CN113811333B (zh) 靶向抗癌核激素受体的化合物
KR101848131B1 (ko) 저용량 이리노테칸염산염 수화물을 함유하는 항종양제
CN117580839A (zh) 抗癌核激素受体靶向化合物
KR100847413B1 (ko) 피리도인돌론 유도체 및 항암제 기재의 약제 조합물
US7816368B2 (en) Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics
ES2982346T3 (es) Sales metálicas y usos de las mismas
KR101847252B1 (ko) 이리노테칸염산염 수화물을 함유하는 항종양제
JP4599164B2 (ja) ３位が複素環式基によって置換されたピリドインドロン誘導体、それらの製造法およびそれらの治療用途
HK1060066B (en) Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents
NZ740252A (en) Antitumor agent including low-dose irinotecan hydrochloride hydrate
NZ740252B2 (en) Antitumor agent including low-dose irinotecan hydrochloride hydrate

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20110715

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20110715

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000